CSY China Sky One Medicl

HARBIN, China, July 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (AMEX:CSY), a leading fully integrated pharmaceutical company producing external use, over- the-counter drugs in the People's Republic of China ("PRC"), announced today that it has 11 new drugs that have entered into clinical trials, including seven administered by injection. China Sky One has a history of successfully producing external use drugs and has now set its sights on developing drugs for injection, a market where it sees a great deal of potential. Out of the 11 new drugs currently undergoing clinical trials that are listed below, seven of them are administered by injection: -- Povidone Iodine Suppository: for treatment of moniliasis colpitis, bacterial colpitis, and hemorrhoids; -- Gabexate Mesylate Injection: for treatment of acute pancreatitis and acute hemorrhagic necrosis of the pancreas; -- Ciclopirox Ointment: for treatment of superficial fungal infection, such as Tinea manuum and Tinea pedis; -- Ciclopirox Olamine Vaginal Suppositories: for treatment of moniliasis, or mycotic colitis. -- Fibrauretnire Suppositories: for treatment of vulvar moniliasis vaginosis; -- Omeprazole Sodium Injection: for treatment of digestive ulcers, gastrinoma, stress ulcers and Reflux Esophagitis. This drug can prevent stress states and upper postoperative digestive tract bleeding and aspiration pneumonitis by general anesthetics; -- Ozagrel Sodium Injection: for treatment of acute cerebral infarction and accompanied impediments; -- Citicoline Sodium Injection: for treatment of acute brain injury and postoperative consciousness impediment; -- Tiopronin Injection: for improving liver function from liver inflammation, fatty liver, alcoholic hepatitis, medication injury, and heavy metal detox. This drug can reduce toxic and side effects of chemotherapy and has a notable curative effect on cataracts and vitreous opacities in early stages -- Carbazochrome Sodium Sulfonate Injection: for treatment of the urinary system, upper digestive tract, respiratory system and obstetric hemorrhage; -- Diltiazem Hydrochloride Injection: for treatment of paroxysmal supraventricular tachycardia and unstable angina pectoris. This drug can also be used for high-blood pressure during an operation or for severe hypertension. "We are very excited about our pipeline of newly developed drugs," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. "They are now in clinical trials and we are confident that they can expand our market share and increase profitability going forward. Our move into the injectable drug delivery market represents a strong opportunity for future growth since the traditional injection is still a dominant delivery method. The testing for these drugs needs about six month to complete and may submit them to the SFDA for approval in the beginning of 2009." About China Sky One Medical, Inc. China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com/ . Safe Harbor Statement Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. For more information, please contact: Company Contact: China Sky One Medical, Inc. Ms. Yanwei Zhang, Board Secretary Tel: +86-451-53994064 Email: Investor Relations Contact: CCG Elite Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: Mr. Richard Micchelli, Financial Writer Tel: +1-646-454-4516 Email: Web: http://www.ccgelite.com/ DATASOURCE: China Sky One Medical, Inc. CONTACT: Company Contact: China Sky One Medical, Inc., Ms. Yanwei Zhang, Board Secretary, +86-451-53994064 or ; Investor Relations Contact: CCG Elite Investor Relations, Mr. Crocker Coulson, President, +1-646-213-1915, or ; Mr. Richard Micchelli, Financial Writer, +1-646-454-4516, or Web Site: http://www.skyonemedical.com/ http://www.ccgelite.com/

Copyright